Novel AAV Capsids
Adeno-Associated Virus (AAV) vectors are among the most widely used delivery systems in gene therapy due to their safety profile, ability to transduce dividing and non-dividing cells, and long-term gene expression.
AAVnerGene's Novel AAV Capsids
ATHENA platform includes three different sub-platform: ATHENA-I, ATHENA-II, ATHENA-III. By combining the three sub-platforms with AI, the ATHENA platform can efficiently identify, evolve and create the best AAV capsids for specific applications, potentially improving the effectiveness of gene therapy and reducing costs.
